Vergelijking

Carbetocin vs. Glepaglutide

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

37025-55-1

geen gegevens

Molecuulmassa

geen gegevens

Halfwaardetijd

0.67 h

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Carbetocin

Carbetocin is an oxytocin receptor agonist with prolonged duration. It triggers a sustained contraction of the uterus after birth, preventing atonic hemorrhage — unlike oxytocin, without a multi-hour infusion.

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Carbetocin	Glepaglutide
Duitsland	Op recept	Niet goedgekeurd
Verenigde Staten	Niet goedgekeurd	Niet goedgekeurd

Volledige vermeldingen

Carbetocin

Volledige vermelding →

Glepaglutide

Volledige vermelding →

Frequently asked questions

What is the difference between Carbetocin and Glepaglutide?: Carbetocin is classified as "Onderzoek (overig)", while Glepaglutide is classified as "Onderzoek (overig)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Carbetocin or Glepaglutide?: The highest available evidence level is "Humane RCT" for Carbetocin and "Humane RCT" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Carbetocin and Glepaglutide in Germany and the United States?: Duitsland: Carbetocin — Op recept, Glepaglutide — Niet goedgekeurd. Verenigde Staten: Carbetocin — Niet goedgekeurd, Glepaglutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Carbetocin

Glepaglutide

Duitsland

Op recept

Niet goedgekeurd

Verenigde Staten

Niet goedgekeurd

Frequently asked questions

What is the difference between Carbetocin and Glepaglutide?

Carbetocin is classified as "Onderzoek (overig)", while Glepaglutide is classified as "Onderzoek (overig)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Carbetocin or Glepaglutide?

The highest available evidence level is "Humane RCT" for Carbetocin and "Humane RCT" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Carbetocin and Glepaglutide in Germany and the United States?

Duitsland: Carbetocin — Op recept, Glepaglutide — Niet goedgekeurd. Verenigde Staten: Carbetocin — Niet goedgekeurd, Glepaglutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.